---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-060406"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2022-09-30T23:59:59+00:00"
generated_at: "2026-06-23T06:19:41.703850+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma closes $5.75M public offering at $5/share, uplists to Nasdaq; appoints new CFO and director

## Summary
- Closed underwritten offering of 1,150,000 shares (incl. full over-allotment) at $5.00/share, gross proceeds $5.75M, net ~$4.83M.
- Common stock began trading on Nasdaq Capital Market under ticker SILO on September 27, 2022.
- CFO Eric Weisblum resigned; remains CEO and President. Daniel Ryweck appointed CFO with $42,000 annual base salary.
- Board appointed Dr. Jeff Pavell as director and chair of nominating and corporate governance committee.
- Proceeds to fund product development, marketing, working capital, and potential acquisitions.

## SEC filing metadata
- accession: 0001213900-22-060406
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2022-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/0001213900-22-060406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/ea166467-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-060406
- JSON: https://secwatch.observer/filing/0001213900-22-060406.json
- Plain text: https://secwatch.observer/filing/0001213900-22-060406.txt

## Key facts
- Executive change
  Daniel Ryweck was appointed as Chief Financial Officer at Silo Pharma, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On September 27, 2022, the Board appointed Daniel Ryweck as Chief Financial Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/0001213900-22-060406-index.htm
- Executive change
  Eric Weisblum resigned as Chief Financial Officer at Silo Pharma, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On September 27, 2022, Eric Weisblum resigned as our Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/0001213900-22-060406-index.htm
- Executive change
  Jeff Pavell was appointed as Director at Silo Pharma, Inc..
  - Action: appointed
  - Role: Director
  source text: On September 27, 2022, the Company’s Board of Directors (the “Board”) appointed Jeff Pavell as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/0001213900-22-060406-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.